Praxis Precision Medicines (PRAX) COO reports tax withholding of 885 shares

Rhea-AI Filing Summary

Praxis Precision Medicines Chief Operating Officer Megan Sniecinski reported an automatic withholding of 885 shares of common stock on January 12, 2026. The issuer retained these shares to satisfy tax withholding obligations that arose when previously reported restricted stock units vested, rather than through an open-market sale.

After this tax-related withholding, Sniecinski beneficially owns 28,530 shares of Praxis Precision Medicines common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sniecinski Megan

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	885	$275.74	$244K

Holdings After Transaction: Common Stock — 28,530 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sniecinski Megan

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		F(1)		885	D	$275.74	28,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRAX COO Megan Sniecinski report?

Megan Sniecinski, Chief Operating Officer of Praxis Precision Medicines, reported that 885 shares of common stock were withheld by the issuer on January 12, 2026 to cover tax obligations from vesting restricted stock units.

Was the PRAX Form 4 transaction an open-market sale by the COO?

No. The Form 4 states that the 885 shares were withheld by the issuer to satisfy tax withholding obligations tied to the vesting of previously reported restricted stock units, not a discretionary open-market sale by Megan Sniecinski.

How many PRAX shares does Megan Sniecinski own after this Form 4 transaction?

Following the tax withholding transaction, Megan Sniecinski is reported to beneficially own 28,530 shares of Praxis Precision Medicines common stock, held directly.

What does transaction code "F" mean in the PRAX Form 4 filing?

Transaction code "F" on the Form 4 indicates that the reported 885 shares were used to pay tax withholding in connection with the vesting of equity awards, as confirmed by the footnote in the filing.

What role does Megan Sniecinski hold at Praxis Precision Medicines (PRAX)?

The Form 4 identifies Megan Sniecinski as an officer of Praxis Precision Medicines, serving as the company’s Chief Operating Officer.